Predictive Oncology Net Worth
Predictive Oncology Net Worth Breakdown | POAI |
Predictive Oncology Net Worth Analysis
Predictive Oncology's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Predictive Oncology's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Predictive Oncology's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Predictive Oncology's net worth analysis. One common approach is to calculate Predictive Oncology's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Predictive Oncology's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Predictive Oncology's net worth. This approach calculates the present value of Predictive Oncology's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Predictive Oncology's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Predictive Oncology's net worth. This involves comparing Predictive Oncology's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Predictive Oncology's net worth relative to its peers.
Enterprise Value |
|
To determine if Predictive Oncology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Predictive Oncology's net worth research are outlined below:
| Predictive Oncology is way too risky over 90 days horizon | |
| Predictive Oncology may become a speculative penny stock | |
| Predictive Oncology appears to be risky and price may revert if volatility continues | |
| Predictive Oncology has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 1.78 M. Net Loss for the year was (13.98 M) with profit before overhead, payroll, taxes, and interest of 1.05 M. | |
| Predictive Oncology currently holds about 25.39 M in cash with (13.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32. | |
| Latest headline from finance.yahoo.com: Predictive Oncology Announces Planned European Launch of its ChemoFx Treatment Selection Marker and Tumor Profiling Assay |
Predictive Oncology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Predictive Oncology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Predictive Oncology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Predictive Oncology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Predictive Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Predictive Oncology backward and forwards among themselves. Predictive Oncology's institutional investor refers to the entity that pools money to purchase Predictive Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Psi Advisors, Llc | 2024-09-30 | 399 | Bank Of America Corp | 2024-09-30 | 51.0 | Royal Bank Of Canada | 2024-09-30 | 50.0 | Jane Street Group Llc | 2024-09-30 | 0.0 | Pfs Partners, Llc | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Renaissance Technologies Corp | 2024-09-30 | 0.0 | Raymond James & Associates | 2024-06-30 | 0.0 | Jpmorgan Chase & Co | 2024-06-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 71.3 K | Geode Capital Management, Llc | 2024-09-30 | 51.9 K |
Follow Predictive Oncology's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.33 M.Market Cap |
|
Project Predictive Oncology's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.89) | (0.93) | |
| Return On Capital Employed | (1.53) | (1.61) | |
| Return On Assets | (0.87) | (0.92) | |
| Return On Equity | (1.94) | (2.04) |
When accessing Predictive Oncology's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Predictive Oncology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Predictive Oncology's profitability and make more informed investment decisions.
Evaluate Predictive Oncology's management efficiency
Predictive Oncology has return on total asset (ROA) of (0.558) % which means that it has lost $0.558 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4936) %, meaning that it created substantial loss on money invested by shareholders. Predictive Oncology's management efficiency ratios could be used to measure how well Predictive Oncology manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.93. The current Return On Capital Employed is estimated to decrease to -1.61. As of now, Predictive Oncology's Net Tangible Assets are increasing as compared to previous years.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.85 | 1.95 | |
| Tangible Book Value Per Share | 1.80 | 1.89 | |
| Enterprise Value Over EBITDA | (0.50) | (0.53) | |
| Price Book Value Ratio | 1.44 | 1.37 | |
| Enterprise Value Multiple | (0.50) | (0.53) | |
| Price Fair Value | 1.44 | 1.37 | |
| Enterprise Value | 8.4 M | 12.6 M |
Evaluating the management effectiveness of Predictive Oncology allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Predictive Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 6.5038 | Revenue | Quarterly Revenue Growth (0.43) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Predictive Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Predictive Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Predictive Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Predictive Oncology time-series forecasting models is one of many Predictive Oncology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Predictive Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Predictive Oncology Earnings per Share Projection vs Actual
Predictive Oncology Corporate Management
| Joshua MBA | Interim Officer | Profile | |
| BS BSc | VP RD | Profile | |
| Pamela MBA | Chief Officer | Profile | |
| Raymond Vennare | CEO Chairman | Profile | |
| DSc OD | VP Operations | Profile | |
| Julia Kirshner | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share | Quarterly Revenue Growth (0.43) | Return On Assets | Return On Equity |
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.